Atrial Fibrillation Ablation in Congenital Heart Disease: Therapeutic Challenges and Future Perspectives
Amalia Baroutidou(Aristotle University of Thessaloniki), George Giannakoulas(AHEPA University Hospital), Nikolaos Otountzidis(Aristotle University of Thessaloniki), Αναστάσιος Κάρτας(Aristotle University of Thessaloniki), Dimitrios V. Moysidis(Aristotle University of Thessaloniki), Αndreas S. Papazoglou(Aristotle University of Thessaloniki), Vasileios Kamperidis(Aristotle University of Thessaloniki), Lilian Mantziari(Interbalkan Medical Center), Antonios Ziakas(Aristotle University of Thessaloniki)
Cited by 13
Related Papers
2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension
|European Heart Journal|2022|3.6k
COVID-19 in Adults With Congenital Heart Disease
|Journal of the American College of Cardiology|2021|76
Prognostic significance of diabetes mellitus in patients with atrial fibrillation
|Cardiovascular Diabetology|2021|48
Riociguat treatment in patients with chronic thromboembolic pulmonary hypertension: Final safety data from the EXPERT registry
|Respiratory Medicine|2020|35
Haemoptysis in Pulmonary Arterial Hypertension Associated with Congenital Heart Disease: Insights on Pathophysiology, Diagnosis and Management
|Journal of Clinical Medicine|2022|22